Xlife Sciences AG
Develops and commercializes early-stage life sciences research projects.
XLS | SW
Overview
Corporate Details
- ISIN(s):
- CH0461929603 (+1 more)
- LEI:
- 984500AH590BE88BB517
- Country:
- Switzerland
- Address:
- Talacker 35, 8001 Zürich
Description
Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-20 02:00 |
Xlife Sciences veröffentlicht Ergebnisse 2022 und Ausblick 2023
|
German | HTML • 24.1 KB | ||
| 2023-02-16 07:00 |
saniva diagnostics receives approval from the US FDA
for its medical product Ne…
|
English | HTML • 11.6 KB | ||
| 2023-02-16 01:00 |
saniva diagnostics receives approval from the US FDA
for its medical product Ne…
|
English | HTML • 10.1 KB | ||
| 2023-02-16 01:00 |
saniva diagnostics erhält Genehmigung der US-Gesundheitsbehörde FDA für ihr Med…
|
German | HTML • 12.6 KB | ||
| 2023-01-23 07:00 |
Stifel initiates research coverage of Xlife Sciences
|
English | HTML • 10.6 KB | ||
| 2023-01-23 01:00 |
Stifel initiates research coverage of Xlife Sciences
|
English | HTML • 9.1 KB | ||
| 2023-01-23 01:00 |
Aufnahme der Research-Abdeckung von Xlife Sciences durch Stifel
|
German | HTML • 9.7 KB | ||
| 2023-01-20 07:00 |
Xlife Sciences: Swiss portfolio company Axenoll receives strategically signific…
|
English | HTML • 11.0 KB | ||
| 2023-01-20 01:00 |
Xlife Sciences: Swiss portfolio company Axenoll receives strategically signific…
|
English | HTML • 9.3 KB | ||
| 2023-01-20 01:00 |
Xlife Sciences: Schweizer Portfoliogesellschaft Axenoll erhält strategisch bede…
|
German | HTML • 9.5 KB | ||
| 2023-01-16 07:00 |
Xlife Sciences portfolio company launches project to research a potential thera…
|
English | HTML • 18.1 KB | ||
| 2023-01-16 01:00 |
Xlife Sciences portfolio company launches project to research a potential thera…
|
English | HTML • 15.1 KB | ||
| 2023-01-16 01:00 |
Xlife Sciences-Portfoliogesellschaft startet Projekt zur Erforschung einer pote…
|
German | HTML • 14.4 KB | ||
| 2022-12-01 07:01 |
Portfolio company Lysatpharma and joint venture Novaxomx start with research an…
|
English | HTML • 11.8 KB | ||
| 2022-12-01 01:00 |
Portfolio company Lysatpharma and joint venture Novaxomx start with research an…
|
English | HTML • 10.1 KB |
Automate Your Workflow. Get a real-time feed of all Xlife Sciences AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xlife Sciences AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xlife Sciences AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-15 | N/A | Executive member | Buy | None | 6,000.00 CHF |
| 2022-06-15 | N/A | Executive member | Buy | None | 3,000.00 CHF |
| 2022-06-14 | N/A | Executive member | Buy | None | 15,500.00 CHF |
| 2022-06-10 | N/A | Executive member | Buy | None | 6,728.90 CHF |
| 2022-06-07 | N/A | Executive member | Buy | None | 34,800.00 CHF |
| 2022-06-03 | N/A | Executive member | Buy | None | 3,540.00 CHF |
| 2022-05-24 | N/A | Executive member | Buy | None | 3,400.00 CHF |
| 2022-05-17 | N/A | Executive member | Buy | None | 10,794.20 CHF |
| 2022-05-13 | N/A | Executive member | Buy | None | 3,690.00 CHF |
| 2022-05-10 | N/A | Executive member | Buy | None | 1,935.00 CHF |
Peer Companies
